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OBJECTIVE—Although intensive glycemic control achieved
with insulin therapy increases the incidence of both moderate
and severe hypoglycemia, clinical reports of cognitive impair-
ment due to severe hypoglycemia have been highly variable. It
was hypothesized that recurrent moderate hypoglycemia precon-
ditions the brain and protects against damage caused by severe
hypoglycemia.
RESEARCH DESIGN AND METHODS—Nine-week-old male
Sprague-Dawley rats were subjected to either 3 consecutive days
of recurrent moderate (25–40 mg/dl) hypoglycemia (RH) or
saline injections. On the fourth day, rats were subjected to a
hyperinsulinemic (0.2 units  kg
1  min
1) severe hypoglycemic
(11 mg/dl) clamp for 60 or 90 min. Neuronal damage was
subsequently assessed by hematoxylin-eosin and Fluoro-Jade B
staining. The functional signiﬁcance of severe hypoglycemia–
induced brain damage was evaluated by motor and cognitive
testing.
RESULTS—Severe hypoglycemia induced brain damage and
striking deﬁcits in spatial learning and memory. Rats sub-
jected to recurrent moderate hypoglycemia had 62–74% less
brain cell death and were protected from most of these
cognitive disturbances.
CONCLUSIONS—Antecedent recurrent moderate hypoglyce-
mia preconditioned the brain and markedly limited both the
extent of severe hypoglycemia–induced neuronal damage and
associated cognitive impairment. In conclusion, changes brought
about by recurrent moderate hypoglycemia can be viewed,
paradoxically, as providing a beneﬁcial adaptive response in that
there is mitigation against severe hypoglycemia–induced brain
damage and cognitive dysfunction. Diabetes 59:1055–1062,
2010
H
ypoglycemia is the major obstacle in achieving
tight glycemic control in people with diabetes
(1). Intensive insulin therapy increases the risk
of iatrogenic hypoglycemia (2). Episodes of
both moderate and severe hypoglycemia have long-term
clinical consequences. Recurrent moderate hypoglycemia
induces a maladaptive response that limits symptoms of
hypoglycemia (hypoglycemia unawareness), limits the
counterregulatory response to subsequent hypoglycemia
(hypoglycemia-associated autonomic failure), and thus
jeopardizes patient safety (1). By depriving the brain of
glucose, more severe hypoglycemia causes brain damage
in animal studies and leads to long-term impairments in
learning and memory (3,4). However, studies examining
the effect of severe hypoglycemia in humans are conﬂict-
ing. Severe hypoglycemia has been shown to alter brain
structure (5–7) and cause signiﬁcant cognitive damage in
many (5,7–12) but not all (13–16) studies. Reasons for the
discrepancy between human and animal studies are un-
known, but a major contributing factor may be the extent
of glycemia control (including recurrent hypoglycemia)
prior to the episode of severe hypoglycemia.
In other models of brain damage, such as ischemic
stroke, brief, mild episodes of antecedent brain ischemia
has been shown to cause a beneﬁcial adaptation that
protects the brain against a subsequent episode of more
severe ischemia (a phenomena known as ischemic precon-
ditioning) (17). In a similar fashion, antecedent, recurrent
episodes of moderate hypoglycemia were hypothesized to
protect the brain against damage caused by a subsequent
episode of more severe hypoglycemia.
To investigate this hypothesis, recurrent moderately
hypoglycemic (25–40 mg/dl) rats (RH rats) and control
saline-injected rats (CON rats) were subjected to hyperin-
sulinemic, severe hypoglycemic clamps (10–15 mg/dl).
One group of rats was killed 1 week after severe hypogly-
cemia to quantify brain damage, while a second group of
rats was evaluated by behavioral and cognitive tests 6–8
weeks after the severe hypoglycemia. The results demon-
strated that recurrent antecedent moderate hypoglycemia
preconditioned the brain and protected it against neuro-
logical damage and cognitive defects induced by an epi-
sode of severe hypoglycemia.
RESEARCH DESIGN AND METHODS
Nine-week-old male Sprague-Dawley rats (Charles River Laboratories) were
individually housed in a temperature- and light-controlled environment main-
taining the animal’s diurnal cycle (12 h light and 12 h dark) with an ad libitum
standard rat chow diet. All studies were done in accordance with the Animal
Studies Committee at the Washington University School of Medicine.
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tree Scientiﬁc) catheters were inserted into the left carotid artery and into the
right jugular vein of anesthetized rats (40–80 mg/kg ketamine with 5–8 mg/kg
xylazine). To maintain patency, catheters were ﬁlled with 40% polyvinylpyr-
rolidone (Sigma) in heparin (1,000 units/ml; USP) (Baxter Healthcare Cor-
poration).
Recurrent moderate hypoglycemia (hypoglycemic preconditioning).
One week after catheter implantation, recurrent moderate hypoglycemia was
induced in nonfasted rats with injections of subcutaneous regular human
insulin (Lilly) (6 units/kg on day 1, 5 units/kg on day 2, and 4 units/kg on day 3),
while CON rats were given equal-volume saline injections for 3 consecutive
days. Food was withheld, and tail-vein blood glucose values were measured
hourly. For insulin-treated rats, recurrent hypoglycemia resulted in blood
glucose levels of 25–40 mg/dl for 3 h. To terminate moderate hypoglycemia,
rats were given a subcutaneous injection of dextrose (Hospira) and were
allowed free access to food.
Hyperinsulinemic-severe hypoglycemia clamp. Animals were fasted over-
night after the third day of injections and the following morning were
subjected to a hyperinsulinemic (0.2 units  kg
1  min
1) severe hypoglycemic
clamp (Fig. 1). Rats were awake, unrestrained, and had free access to water.
Arterial blood glucose was measured every 15 min with Ascensia Contour
glucose monitors (Bayer HealthCare), which are reported to have accurate
blood glucose readings in the hypoglycemia range, although accuracy in the
severe hypoglycema range has not been reported. Insulin and glucose were
coinfused intravenously to lower blood glucose to 10–15 mg/dl, as this level of
severe hypoglycemia was necessary to induce neuronal damage (3,18). Severe
hypoglycemia (SH rats) was maintained between 10 and 15 mg/dl for either 60
min (CON-SH60, n  6; RH-SH60, n  10) or 90 min (CON-SH90, n  20;
RH-SH90, n  18) for the CON and RH-treated rats, respectively. To
terminate hypoglycemia, insulin infusion was stopped and infusions of
dextrose were given until animals could maintain euglycemia. Additional
blood samples were obtained during the basal period and 2 h into the
hyperinsulinemic clamp when severe hypoglycemia had been reached for
30 min for epinephrine measurements, as determined by the single-isotope
derivative method (19).
Tonic-clonic seizure-like behavior was visually noted by characteristic
brief (5–10 s) neck extensions, tonic stretching, uncontrolled limb move-
ments, and spontaneous spinning (18,20). The number of episodes of seizure-
like behavior during the clamp was quantiﬁed for each rat and was later
correlated with histological and cognitive ﬁndings.
Two other groups of rats were made either recurrently hypoglycemic or
given saline injections as described above and, on the fourth day, underwent
a 90-min hyperinsulinemic-euglycemic (0.2 units  kg
1  min
1) clamp
(CON-euglycemic [EUG], n  9; RH-EUG, n  11). These two additional
groups served as euglycemic control rats treated in the same fashion except
that they were not exposed to severe hypoglycemia.
The ﬁrst grouping of rats that underwent hyperinsulinemic severe hypo-
glycemic clamps or hyperinsulinemic-euglycemic clamps was analyzed for
brain damage. The second grouping of rats was subjected to the same
hyperinsulinemic clamp protocols except that they underwent sensorimotor
and behavioral testing (Fig. 1).
Histology. One week after the severe hypoglycemic or euglycemic clamps,
anesthetized rats were intracardially perfused with 0.01 mol/l PBS (Sigma)
followed by 4% paraformaldehyde (Electron Microscopy Sciences, Hatﬁeld,
PA). Brains were immersed in 4% paraformaldehyde overnight and then
cryoprotected in 30% sucrose. Beginning at 2.8 mm posterior to the bregma,
coronal cryostat sections (20 m) were collected on Superfrost coated slides
(VWR). Four coronal sections, 120 m apart, were analyzed for neuronal
damage by Fluoro-Jade B (Chemicon International) and hematoxylin-eosin
(H-E) (Sigma) staining according to the manufacturer’s protocol. Fluoro-
Jade B is a well-characterized stain for degenerating neurons (21).
Fluorescent cells (Fluoro-Jade–positive cells) were quantiﬁed in both
hemispheres of the cortex and of the hippocampal structures CA1 and
dentate gyrus. For each region of interest, data are expressed as the
average number of Fluoro-Jade B–positive (FJB
) cells per section.
(CON-SH90, n  9; RH-SH90, n  8).
Behavioral testing. Consistent with other protocol designs (4,22,23), his-
topathological outcomes were assessed 1 week following the hypoglycemic
neuronal insult, while cognitive studies were performed 6–8 weeks later in a
separate group of similarly treated rats. This later assessment of cognitive
function is a more useful measure of clinical outcome and a better functional
index of neuroprotection because it allows for a complete and integrated
evaluation of ongoing damage and possible recovery (24). Because the Morris
water maze test is a measure of hippocampal-dependent spatial learning/
memory and because the rats that underwent 60 min of severe hypoglycemia
had little damage in the hippocampus, cognitive testing was not performed in
this group. Cognitive testing was performed in the rats that underwent 90 min
of severe hypoglycemia because these animals had marked damage in the
hippocampus. After a 6- to 8-week recovery from the severe hypoglycemic
(CON-SH90, n  11; RH-SH90, n  9) and euglycemic (CON-EUG, n  7;
RH-EUG, n  9) clamps, rats were transferred to the behavioral testing
facility and allowed 1 week to acclimate before locomotor activity,
sensorimotor measures, and Morris maze tests were performed under
euglycemic conditions.
One-hour locomotor activity test and sensorimotor battery. General
locomotor activity and exploratory behavior were evaluated for 1 h using a
computerized system (MotorMonitor; Kinder Scientiﬁc) of photobeam pairs to
quantify ambulations (whole body movements) and rearing frequency. As
previously described (25), the ledge, platform, 90
o-inclined screen, and
walking initiation tests were conducted to measure balance, strength, coor-
dination, and initiation of movement.
Water maze cognitive testing. Spatial learning and memory were assessed
using the Morris water maze test similarly to previously published methods
(25). Brieﬂy, a computerized tracking program (Polytrack; San Diego Instru-
ments) recorded the swim-path lengths and time required to ﬁnd the platform.
For the cued trials, rats were trained to swim to the submerged platform (1.5
cm below the surface) marked (cued) by a visible pole. Spatial learning
capabilities of the rats were tested during the place trials. In the place trials,
rats were trained to learn the position of a submerged and nonvisible platform
that remained in the same location across all trials. To evaluate memory
retention of the platform location, a probe trial was conducted 1 h after the
last place trial, which involved removing the platform from the pool and
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FIG. 1. Experimental protocol. Arterial and venous catheters were implanted into 9-week-old Sprague-Dawley rats. After 1 week of recovery,
animals were either given an insulin injection daily for 3 consecutive days to induce moderate hypoglycemia (25–40 mg/dl) or they were given
saline injections as a control. On the fourth day, rats underwent a severe hypoglycemic (10–15 mg/dl) hyperinsulinemic (0.2 units  kg
1  min
1)
clamp for either 60 or 90 min or, alternatively, underwent a 90-min euglycemic (80 mg/dl) hyperinsulinemic (0.2 units  kg
1  min
1) clamp.
Animals were either killed 1 week later to assess neuronal damage by H-E and Fluoro-Jade B staining or underwent sensorimotor and cognitive
testing 6–8 weeks following the clamp.
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included the following: the number of times a rat passed directly over the
platform location (platform crossings), the time spent in the target quadrant
versus the time spent in each of the other pool quadrants (spatial bias), and
average proximity (distance to the platform location sampled and averaged
across 1-s epochs throughout the trial).
Statistical analysis. All data are expressed as means  SEM. Statistical
analyses were performed by either Student’s t tests or ANOVA. Quantiﬁcation
of brain damage and behavioral assessments were made by investigators
blinded to treatment conditions.
RESULTS
Recurrent hypoglycemia reduced cortical brain dam-
age induced by 60 min of severe hypoglycemia. No
signiﬁcant differences in blood glucose were observed
before, during, or after the 60-min severe hypoglycemic
clamps between RH and CON rats (Fig. 2A). As expected,
RH-SH60 rats had an attenuated epinephrine response
to hypoglycemia compared with CON-SH60 rats (2001 
241 and 3,487  474 pg/ml; P  0.01) (supplementary
Fig. 1, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1495/DC1). Im-
portantly, RH-SH60 rats had 64% less neuronal damage, as
assessed by the number of FJB
 cells, in the cortex than
CON-SH60 rats (173  64 vs. 479  170 cells; P  0.05)
(Fig. 2B and C). Of note, 60 min of severe hypoglycemia
did not induce signiﬁcant damage in the hippocampus in
either RH-SH60 or CON-SH60 rats.
Recurrent hypoglycemia attenuated cortical and hip-
pocampal brain injury after 90 min of severe hypo-
glycemia. To consistently induce hypoglycemic brain
damage in the hippocampus, the above experiments were
repeated except that the duration of severe hypoglycemia
was extended to 90 min. The average blood glucose during
90 min of severe hypoglycemia was 10.9  0.2 vs. 11.0 
0.3 mg/dl in the CON-SH90 and RH-SH90 rats, respectively
(P  NS) (Fig. 3C). As an additional set of experimental
controls, euglycemic-hyperinsulinemic clamps were also
performed in RH-EUG (n  2) or CON-EUG (n  2) rats.
Blood glucose was maintained at 76  5 and 84  6 mg/dl
in the CON-EUG and RH-EUG rats, respectively (P  NS)
(Fig. 3C).
Again validating the model of hypoglycemia-associated
autonomic failure, RH reduced the epinephrine response
to hypoglycemia (CON-SH90 3,175  516 mg/dl and RH-
SH90 2077  426 pg/ml; P  0.05) (supplementary Fig. 1).
Severe hypoglycemia of 90 min induced signiﬁcant cellular
damage in the cortex, as evidenced by the presence of
pyknotic cells observed with H-E staining (Fig. 3A) and the
marked number of ﬂuorescent cells with Fluoro-Jade B
staining (Fig. 3B). Interestingly, 90 min of severe hypogly-
cemia induced sixfold-greater cortical neuronal damage
than 60 min of severe hypoglycemia (Figs. 2C and 3D).
Recurrent antecedent moderate hypoglycemia decreased
cortical brain damage induced by 90 min of severe hypo-
glycemia by 62% (RH-SH90 1,107  428 FJB
 cells and
CON-SH90 2,918  615 FJB
 cells; P  0.05). Unlike 60
min of severe hypoglycemia, 90 min of severe hypoglyce-
mia did induce hippocampal brain damage (Fig. 3).
Recurrent antecedent hypoglycemia resulted in less hip-
pocampal brain damage following 90 min of severe hypo-
glycemia compared with that in CON-SH90 rats (Fig. 3).
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FIG. 2. Recurrent hypoglycemia attenuates brain damage after
60 min of severe hypoglycemia. A: Blood glucose levels are
shown in rats subjected to a 60-min severe hypoglycemic (10–15
mg/dl) hyperinsulinemic (0.2 units  kg
1  min
1) clamp. Blood
glucose was not signiﬁcantly different between CON-SH6 (open
circles) (n  6) and RH-SH60 (closed circles) (n  10) rats
during 60 min of severe hypoglycemia. B: Representative H-E
(top panel) and Fluoro-Jade B–positive (bottom panel) staining
of the cortex of CON-SH60 and RH-SH60 rats 1 week following
60 min of severe hypoglycemia. Neuronal damage is indicated by
pyknotic cells (H-E staining; green arrows) or with Fluoro-Jade
B–positive cells (green ﬂuorescence). Scale bar  100 m. C:
Quantiﬁcation of Fluoro-Jade B staining in CON-SH60 (white
bar) (n  6) and RH-SH60 (black bar) (n  10) rats. Following
severe hypoglycemia, RH rats had signiﬁcantly fewer degener-
ating cells in the cortex than CON rats (*P < 0.05, by Student’s
t test). (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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 cells in the
CA1 region by 74% (RH-SH90 88  56 cells vs. CON-SH90
334  91 cells; P  0.05) and by 67% in the dentate gyrus
(RH-SH90 274  119 cells vs. CON-SH90 833  148 cells;
P  0.05) compared with CON-SH90 (Fig. 3D). No damage
was observed in the hypothalamus in either CON-SH90 or
RH-SH90 rats (supplementary Fig. 2).
Interestingly, recurrent hypoglycemia also reduced the
episodes of seizure-like behavior observed during severe
hypoglycemia (RH-SH90 2.0  0.3 vs. CON-SH90 3.4 
0.3; P  0.01) (Fig. 3E). There was a signiﬁcant corre-
lation between the number of episodes of seizure-like
behavior and number of FJB
 cells (R  0.572; P  0.05)
(Fig. 3F).
In the absence of severe hypoglycemia, virtually no
Fluoro-Jade–positive cells or pyknotic cells (H-E) were
observed in the cortex or hippocampus of either the
CON-EUG or RH-EUG groups (Fig. 3).
Preserved cognitive function in recurrently hypogly-
cemic rats. General activity was not different between
groups (supplementary Fig. 3). The severe hypoglycemic
groups (both CON-SH90 and RH-SH90) exhibited signiﬁ-
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FIG. 3. Recurrent hypoglycemia limits brain cell death 1 week following 90 min of severe hypoglycemia. A: Representative H-E staining of the
cortex and hippocampal structures, CA1, and the dentate gyrus (DG), 1 week following 90-min severe hypoglycemic or euglycemic clamps in
RH-SH90, RH-EUG, CON-SH90, and CON-EUG rats. Rats that underwent severe hypoglycemia had damaged neurons characterized by pyknotic
nuclei (green arrows). Scale bar  100 m. B: Fluoro-Jade B–positive cells (green ﬂuorescence) in the cortex, hippocampal CA1 region, and
dentate gyrus of the same four treatment groups. Scale bar  100 m. C: Blood glucose was not signiﬁcantly different between CON-SH90 (open
circles) (n  9) and RH-SH90 (closed circles) (n  8) rats during 90 min of severe hypoglycemia. Blood glucose was clamped at equal levels of
euglycemia in CON-EUG (open triangles) (n  9) and RH-EUG (closed triangles) (n  11) rats for 90 min. D: Following 90 min of severe
hypoglycemia, the markedly increased number of FJB
 cells in the cortex, CA1, and dentate gyrus observed in the CON-SH90 rats (diagonal
hatch) was signiﬁcantly (*P < 0.05) reduced in RH-SH90 rats (gray horizontal hatch). Bars representing Fluoro-Jade B–positive cells in CON-EUG
and RH-EUG groups are not visible in this ﬁgure because no appreciable brain damage was observed in euglycemic rats not exposed to severe
hypoglycemia. E: CON-EUG and RH-EUG rats experienced no seizure-like behavior. Rats exposed to 90 min severe hypoglycemia exhibited
seizure-like behavior, although RH-SH90 rats had signiﬁcantly less seizure-like behavior than CON-SH90 rats (*P < 0.01). F: In rats that
experienced severe hypoglycemia (RH-SH90 and CON-SH90), seizure-like behaviors positively correlated with the amount of Fluoro-Jade B cells
in the hippocampus (R  0.572; P < 0.05). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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EUG rats (supplementary Fig. 3B). Data from the walking
initiation, ledge, platform, and 90
o-inclined screen were
not signiﬁcantly different between groups (supplementary
Fig. 3C–F).
During the cue (Fig. 4A) and place (Fig. 4B) trials, the
CON-SH90 rats performed worse than the other three
groups in spite of having normal swimming speeds (sup-
plementary Fig. 4). In the cue trials, CON-SH90 rats had
signiﬁcantly longer path lengths across the blocks of trials
than the CON-EUG rats (P  0.0002). Importantly, RH-
SH90 rats had signiﬁcantly shorter path lengths relative to
the CON-SH90 rats (P  0.0025), while no differences were
observed between RH-SH90 and CON-EUG or between the
two EUG control groups.
During the place (spatial learning) trials, the CON-SH90
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gP 
0.014)—similar to euglycemic controls. F: The number of episodes of seizure-like behaviors observed during severe hypoglycemia 6–8 weeks prior
positively correlated with average path length during the place trials (R  0.685; P < 0.001; n  20).
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SH90 rats had signiﬁcantly (P  0.0001) longer path
lengths across the blocks of trials than the CON-EUG rats
(Fig. 4B). Notably, RH-SH90 rats had signiﬁcantly shorter
path lengths than CON-SH90 rats (P  0.0006) (Fig. 4B).
Again, no differences were observed between RH-SH90
and CON-EUG rats or between the two euglycemic groups.
During the probe trial, CON-SH90 rats made signiﬁ-
cantly fewer platform crossings relative to the CON-EUG
rats (P  0.014), though no differences in platform cross-
ings between CON-SH90 and RH-SH90 rats were observed
(Fig. 4C). However, with regard to spatial bias and average
proximity to the platform location, RH-SH90 rats did have
improved performance compared with CON-SH90 rats. In
spatial bias analysis, RH-SH90, CON-EUG, and RH-EUG
rats all exhibited spatial bias for the target quadrant; each
group spent signiﬁcantly more time in the target quadrant
compared with the other pool quadrants (P  0.0025).
CON-SH90 rats did not show signiﬁcant spatial bias (Fig.
4D). Further, CON-SH90 rats had signiﬁcantly higher av-
erage proximity scores than CON-EUG (P  0.014) and
RH-SH90 (P  0.014) rats. RH-SH90 rats performed simi-
larly to CON-EUG rats (Fig. 4E). In summary, during the
probe trial, severe hypoglycemia (CON-SH90 rats) signiﬁ-
cantly impaired all three tests of memory retention, and
antecedent recurrent moderate hypoglycemia pretreat-
ment (RH-SH90 rats) signiﬁcantly improved memory per-
formance on two out of three measures.
Interestingly, the number of episodes of seizure-like
behavior during severe hypoglycemia positively correlated
with performance during Morris water maze testing (Fig.
3F). Speciﬁcally, increases in the number of episodes of
seizure-like behavior were associated with longer average
path lengths (R  0.685; P  0.001) (Fig. 3F).
DISCUSSION
Given that severe hypoglycemia affects 40% of insulin-
treated people with diabetes (26), concern regarding the
hazardous potential for severe hypoglycemia to cause
“brain damage” continues to be a very real barrier for
realizing the full beneﬁts of intensive glycemic control
(27). Patients with the highest incidence of severe hypo-
glycemia are most often those who maintain intensive
glycemic control and, hence, are likely to have had recur-
rent bouts of moderate hypoglycemia. In this study, recur-
rent moderate hypoglycemia preconditioned the brain and
protected it against brain damage and cognitive dysfunc-
tion induced by severe hypoglycemia.
In these experiments, severe hypoglycemic brain injury
was consistently induced with hyperinsulinemic-hypogly-
cemic (15 mg/dl) clamps that carefully controlled the
depth and duration of severe hypoglycemia and avoided
the confounding effects of anesthesia (28–31). The amount
and distribution of neuronal damage was markedly differ-
ent between the 60- and 90-min clamp studies (Figs. 2 and
4). In spite of similar degrees of hypoglycemia (10–15
mg/dl), the extra 30 min of severe hypoglycemia induced a
sixfold increase in cortical brain damage and markedly
increased hippocampal brain damage (which was minimal
in the 60-min clamp). These ﬁndings emphasize the impor-
tance of the duration of severe hypoglycemia, and not
hypoglycemic nadir alone, as a critically important com-
ponent in determining the extent of brain damage and
cognitive dysfunction (22). Of note, the lack of brain-
damaged cells in the euglycemic controls indicated that
experimental conditions other than severe hypoglycemia
(i.e., catheter implantation surgery, recurrent moderate
hypoglycemia, hyperinsulinemic clamp, and glucose infu-
sion) did not cause signiﬁcant brain damage.
The most notable ﬁndings were that rats exposed to 3
days of recurrent moderate hypoglycemia had less brain
injury associated with severe hypoglycemia in both the
cortex and hippocampus. Thus, as with ischemic precon-
ditioning (17), hypoglycemic preconditioning attenuated
brain damage by 62–74%. Although hypoglycemia-induced
neuronal damage in the hypothalamus has been noted
(32), other studies (33) as well as this study observed
no severe hypoglycemia-induced neuronal injury in the
hypothalamus.
In spite of the marked degree of cortical neuronal
damage induced by severe hypoglycemia, the rats had no
meaningful deﬁcit in sensorimotor function as measured
by the locomotor activity and sensorimotor tests. Fur-
ther supporting the absence of gross motor deﬁcits
following severe hypoglycemia was the observation of
no differences between groups in swimming speeds
(supplementary Fig. 4). Importantly, rats exposed to
severe hypoglycemia showed no signs of sensorimotor
impairments that could have affected interpretation of
cognitive function as measured during the Morris water
maze.
Cognitive assessment with water maze testing docu-
mented severe cognitive performance deﬁcits induced by
severe hypoglycemia, and these impairments were pre-
vented by antecedent recurrent moderate hypoglycemia.
Speciﬁcally, analysis of the escape path–length data showed
that severe hypoglycemia signiﬁcantly impaired perfor-
mance relative to that of euglycemic controls during both
the cued and place trials and that recurrent hypoglycemia
completely prevented the impaired performance induced
by severe hypoglycemia (Fig. 4). For the probe trial, three
measures of memory performance were evaluated: plat-
form crossings, spatial bias toward the target quadrant,
and average proximity (Fig. 4). Severe hypoglycemia again
induced signiﬁcant memory impairment in all three
measures. Antecedent recurrent hypoglycemia prevented
these impairments in two of those measures (spatial bias
and average proximity). Regarding platform crossings,
recurrent hypoglycemia tended to improve performance
but not signiﬁcantly (RH-SH90 vs. CON-SH90 rats), indi-
cating that recurrent hypoglycemia was unable to com-
pletely reverse the retention deﬁcits concerning the exact
location of the platform. However, analysis of the spatial
bias and average proximity data demonstrated that recur-
rent hypoglycemia did preserve retention of a more
general platform location. Speciﬁcally, RH-SH90 rats ex-
hibited a spatial bias for the target quadrant, whereas
CON-SH90 rats did not, and CON-SH90 rats had an average
proximity that was farther away from the platform loca-
tion than RH-SH90 rats and the euglycemic controls. These
ﬁndings indicate that memory retention was impaired as a
result of severe hypoglycemia relative to euglycemic controls
in all probe trial variables and that recurrent hypoglycemia
prevented severe hypoglycemia–induced impairments in two
of three probe trial indexes.
Consistent with the notion that recurrent hypoglycemia
induces an adaptive brain response is the observation that
RH-SH90 rats had less seizure-like behavior during severe
hypoglycemia (Fig. 3E), suggesting that the RH-treated
brain better tolerated severe hypoglycemia. A novel ﬁnd-
ing of this study is that the number of episodes of
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mia also correlated with cognitive performance (Fig. 4F).
As in the real-world setting, witnessed hypoglycemic sei-
zures were deﬁned clinically. In the absence of electroen-
cephalogram monitoring, the effect of subclinical seizures
(i.e., seizures not associated with noticeable motor activ-
ity) on brain damage and cognition could not be assessed.
Nonetheless, in these experimental conditions, observable
instances of seizure-like behavior correlated with the
extent of neuronal damage and long-term cognitive func-
tion, and while not causative, the number of seizures
during hypoglycemia was a marker for the extent of
neuronal injury and was prognostic of long-term cognitive
outcomes. Indeed, clinical studies support these ﬁndings
because the presence of hypoglycemic seizures, even
more than severe hypoglycemia per se, correlate more
closely with impaired cognitive function (10,12).
Independent of episodes of severe hypoglycemia, previ-
ous studies have shown that recurrent moderate hypogly-
cemia can alter cognitive function. Recurrent moderate
hypoglycemia did not cause neuronal damage in the
hippocampus (as conﬁrmed in this study) but has been
shown to impair hippocampal long-term potentiation, a
cellular mechanism believed to be involved in learning and
memory (34). Conversely, recurrent hypoglycemia im-
proved cognitive ability in rats tested in an euglycemic
state (35,36). In the current study, recurrent moderate
hypoglycemia-treated control rats not exposed to severe
hypoglycemia did not have impaired or improved cognitive
ability during Morris water maze testing. Since 2–3 weeks
of scrupulous avoidance of hypoglycemia reverses the
hypoglycemia unawareness associated with recurrent hy-
poglycemia (37,38), it is presumed that any effect of
antecedent recurrent hypoglycemia on cognition may have
dissipated during the 6–8 weeks’ recovery prior to cogni-
tive testing.
Although recurrent moderate hypoglycemia leads to
maladaptive responses resulting in hypoglycemia un-
awareness and hypoglycemia-associated autonomic fail-
ure, the mechanism(s) by which recurrent hypoglycemia
leads to these adaptations remains elusive. Similarly, the
current experiments do not identify the mechanisms by
which recurrent moderate hypoglycemia 1) protected
against severe hypoglycemia–induced neuronal damage,
2) limited severe hypoglycemia–induced neurocognitive
dysfunction, or 3) increased thresholds for hypoglycemic
seizures. Putative mechanisms for these beneﬁcial adap-
tations could include glycogen supercompensation (in-
creased brain glycogen content above prehypoglycemic
levels) (39–43). By keeping a higher level of stored fuel
units, increased brain glycogen content has been shown to
reduce hypoglycemic neuronal injury by maintaining brain
electrical activity and forestalling electroencephalogram
isoelectricity (44). Enhanced nutrient transport may also
contribute to the neuroprotective effects of recurrent
hypoglycemia (45,46). Monocarboxylate acid transport is
increased during hypoglycemia in patients with well-con-
trolled type 1 diabetes (45,46). Increased transport of
monocarboxylate acids (e.g., lactate) could provide an
alternative energy source that maintains neuronal function
(4). Other possibilities that could account for the observed
neuroprotective effect of recurrent hypoglycemia could be
altered brain metabolism or neuronal activity (39,47–49).
Recurrent hypoglycemia enhances the inhibitory neuro-
transmitter, -aminobutyric acid, which could reduce neu-
ronal activity and limit excitotoxic damage (48). Further
studies on the precise mechanisms of how recurrent hypo-
glycemia exerts its neuroprotective effects are warranted.
These studies demonstrate that recurrent moderate
hypoglycemia preconditions and protects the brain against
severe hypoglycemia–induced neuronal damage and its
associated cognitive deﬁcits. These intriguing ﬁndings
suggest that recurrent bouts of moderate hypoglycemia
that occur with intensive glycemic control might, paradox-
ically, render an individual more prone but less vulnerable
to an episode of severe hypoglycemia. If the current data
indicating a neuroprotective preconditioning effect of re-
current moderate hypoglycemia were to be extrapolated
to the clinical setting, it could explain the apparent diver-
gent ﬁndings between animal and clinical studies and may
also explain the seemingly incongruous clinical ﬁndings
that intensively treated patients who experience recurrent
moderate and severe hypoglycemia may be paradoxically
protected from severe hypoglycemia–induced brain dam-
age and may not suffer from associated long-term cogni-
tive damage (13,50).
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